Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rationale and statistical methodology for the VISA studies.

M J Ratcliffe1, M J Godley

  • 1Medical Research Department, ICI Pharmaceuticals, Cheshire, United Kingdom.

Drugs
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ontogeny and cloning of B cells in the bursa of Fabricius.

Immunology today·2014
Same author

Ontogeny of pre-B cells in the hatched chicken.

Immunology today·2014
Same author

Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages.

The European respiratory journal·2007
Same author

A positive role for the PP2A catalytic subunit in Wnt signal transduction.

The Journal of biological chemistry·2000
Same author

The chicken B-cell receptor complex and its role in avian B-cell development.

Immunological reviews·2000
Same author

Perinatal deletion of B cells expressing surface Ig molecules that lack V(D)J-encoded determinants in the bursa of Fabricius is not due to intrafollicular competition.

Journal of immunology (Baltimore, Md. : 1950)·2000
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Epanolol (Visacor) offers improved tolerability compared to other antianginal treatments like metoprolol and nifedipine. Patient preference studies confirm its enhanced tolerability profile in managing angina.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Antianginal therapies are crucial for managing coronary artery disease.
  • Epanolol (Visacor) demonstrated comparable efficacy and safety to existing treatments.
  • Initial assessments suggested improved tolerability with epanolol.

Purpose of the Study:

  • To quantify the improved tolerability of epanolol compared to other antianginal drugs.
  • To examine patient preference for epanolol versus metoprolol and nifedipine.
  • To provide a detailed rationale, design, and statistical methodology for these comparative studies.

Main Methods:

  • Two prospective studies were conducted, each involving 500 patients.
  • Study 1: Epanolol (200mg daily) vs. Metoprolol (100mg twice daily).

Related Experiment Videos

  • Study 2: Epanolol (200mg daily) vs. Nifedipine retard (20mg twice daily).

    • Main Results:

    • Epanolol demonstrated equivalent efficacy and safety to metoprolol and nifedipine.
    • Epanolol showed significantly improved tolerability compared to both comparator drugs.
    • Patient preference favored epanolol due to its better tolerability.

    Conclusions:

    • Epanolol is a well-tolerated antianginal therapy with efficacy comparable to established treatments.
    • The improved tolerability of epanolol may enhance patient adherence and treatment outcomes.
    • Further investigation into patient preference highlights the clinical significance of drug tolerability.